Similar articles

• Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.

  Cama C, Olsson CA, Raffo AJ, Perlman H, Buttyan R, O'Toole K, McMahon D, Benson MC, Katz AE. Cama C, et al. J Urol. 1995 May;153(5):1373-8. J Urol. 1995. PMID: 7536252
• Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.

  Millon R, Jacqmin D, Muller D, Guillot J, Eber M, Abecassis J. Millon R, et al. Eur Urol. 1999 Oct;36(4):278-85. doi: 10.1159/000020005. Eur Urol. 1999. PMID: 10473985
• Influence of blood storage and sample processing on molecular detection of circulating prostate cells in cancer.

  Berteau P, Dumas F, Gala JL, Eschwège P, Lacour B, Philippe M, Loric S. Berteau P, et al. Clin Chem. 1998 Mar;44(3):677-9. Clin Chem. 1998. PMID: 9510885 No abstract available.
• Clinical usefulness of RT-PCR detection of hematogenous prostate cancer spread.

  Verkaik NS, Schröder FH, Romijn JC. Verkaik NS, et al. Urol Res. 1997;25(6):373-84. doi: 10.1007/BF01268851. Urol Res. 1997. PMID: 9443645 Review.
• Detection of disseminated prostate cells by reverse transcription-polymerase chain reaction (RT-PCR): technical and clinical aspects.

  Corey E, Corey MJ. Corey E, et al. Int J Cancer. 1998 Aug 31;77(5):655-73. doi: 10.1002/(sici)1097-0215(19980831)77:5<655::aid-ijc1>3.0.co;2-u. Int J Cancer. 1998. PMID: 9688296 Review. No abstract available.